Neurogene Inc. (NASDAQ:NGNE) Stock Has Average Price Target of $79.57

Shares of Neurogene Inc. (NASDAQ:NGNE) have been given an average recommendation of “Buy” by the eight ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $79.57.

Several brokerages recently weighed in on NGNE. Guggenheim boosted their target price on Neurogene from $69.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. JPMorgan Chase & Co. began coverage on Neurogene in a research note on Thursday, October 8th. They issued an “overweight” rating and a $60.00 price target for the company. Wall Street Zen raised Neurogene from a “strong sell” rating to a “sell” rating in a report on Saturday. William Blair upgraded Neurogene to a “strong-buy” rating in a research note on Wednesday, September 23rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a report on Thursday, October 15th.

Neurogene Trading Up 0.1%

Shares of NGNE traded up $0.03 during midday trading on Friday, reaching $23.93. 193,615 shares of the stock were exchanged, compared to its average volume of 312,797. The company has a market capitalization of $495.35 million, a P/E ratio of -4.70 and a beta of 1.75. Neurogene has a 52 week low of $15.93 and a 52 week high of $43.66. The company’s 50 day moving average is $28.21 and its two-hundred day moving average is $28.08.

Neurogene (NASDAQ:NGNE) last issued its quarterly earnings data on Monday, November 9th. The company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.36) by $0.31. On average, sell-side analysts expect that Neurogene will post -5.26 EPS for the current year.

Key Stories Impacting Neurogene

These are some of the NGNE stories that stood out recently:

• Positive Sentiment: HC Wainwright raised its 2026 and 2027 earnings-per-share estimates, projecting narrower losses across the periods and lifting its FY2027 estimate to a loss of $4.80 per share from $4.99. The firm maintained its Buy rating and $60 price target. HC Wainwright forecast for Neurogene
• Positive Sentiment: Canaccord Genuity also reaffirmed its Buy rating on Neurogene, signaling continued analyst confidence. Canaccord Genuity keeps Buy rating
• Negative Sentiment: Despite the improved estimates, HC Wainwright still expects Neurogene to report losses in 2026 and 2027, underscoring its ongoing financial risk.

Hedge Funds Weigh In On Neurogene

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp purchased a new position in shares of Neurogene in the second quarter worth about $904,000. BlackRock Inc. acquired a new position in Neurogene during the second quarter worth about $33,274,000. Renaissance Technologies LLC boosted its position in Neurogene by 210.0% during the first quarter. Renaissance Technologies LLC now owns 43,400 shares of the company’s stock worth $875,000 after acquiring an additional 29,400 shares during the last quarter. Wellington Management Group LLP purchased a new stake in Neurogene during the 2nd quarter valued at about $987,000. Finally, Deutsche Bank AG purchased a new stake in Neurogene during the 2nd quarter valued at about $3,354,000. Institutional investors and hedge funds own 52.37% of the company’s stock.

About Neurogene

Neurogene Inc. is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. Its work focuses on using gene therapy to address the underlying causes of disorders with limited treatment options. The company’s lead program, NGN-401, is an investigational gene therapy for Rett syndrome, a rare genetic disorder that primarily affects girls and can cause significant developmental and neurological challenges. Neurogene is also advancing a broader pipeline of potential genetic medicines for rare diseases.